 
  
 
 
A Mobile Health Intervention in Pulmonary Arterial 
Hypertension  Protocol  
 
 
  
Date:  [ADDRESS_705805] 2019  
  
Version:  4.3 
Principal Investigator:  [INVESTIGATOR_29710] L. Brittain, MD, MSc  
Cardiovascular Medicine  
[ADDRESS_705806], Suite 300A 
Nashville, TN [ZIP_CODE]  Phone:  [PHONE_11225] -322-4382  
Fax: [PHONE_11225] -936-2029  
 
Confidential Information  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  1 
Protocol Date: 08/06/2019  Protocol Summary  
OBJECTIVES : 
The primary objective of this stud y is to test the 
feasibility of a mobile h ealth  (mHealth)  intervention to 
increase mean daily step counts in patients with 
pulmonary arterial hypertension (PAH) after 12 
weeks.  
Secondary objectives include:  
• Change from baseline of six minute  walk test 
distance (meters) at week 12.  
• Change from baseline of RV free wall longitudinal 
strain at week 12 (RV Strain).  
• Assess the frequency that the daily step target 
was achieved over 12 weeks (Daily goal 
attainment).  
• Change in minutes of activity per  day between 
week 12 and baseline (Daily aerobic time).  
• Change in survey score between week 12 and 
baseline (emPHasis -10 Quality of Life survey)  
• Change in survey score between week 12 and 
baseline (SF -36 Quality of Life Mental 
Component Score).  
• Change in B org Dyspnea Score between week 12 
and Baseline.  
• Change in heart rate between week 12 and 
Baseline (Resting heart rate).  
• Change from baseline insulin resistance at week 
12 (HOMA -IR). 
• Change from baseline B -type natiurectic peptide 
level at week 12 (BNP).  
• Change in SF -36 score between week 12 and 
Baseline (SF -36 Physical Component Score).  
• Change in minutes between week 12 and 
baseline in minutes of moderate -vigorous activity.  
• Change in fat volume between week 12 and 
baseline (visceral fat  volume).  
STUDY DESIGN:   
Randomized, single -blind ed, parallel group , Phase II 
study of 50 subjects with PAH. Eligible subjects will 
be randomly assigned to receive the mHealth 
intervention or not for twelve weeks . 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  2 
Protocol Date: 08/06/2019  STUDY POPULATION:          
Inclusion criteria:  
• Adults aged 18 or older.  
• Diagnosed with idiopathic, heritable, or 
associated (connective tissue disease, drugs, or 
toxins) pulmonary arterial hypertension (PAH) 
according to World Health Organization 
consensus recommendations.  
• Stable PAH -specific medication regi men for three 
months prior to enrollment. Subjects with only a 
single diuretic adjustment in the prior three 
months will be included.  
• Subjects must own a Bluetooth capable modern 
smartphone capable of receiving and sending text 
messages .  
• Forced vital capa city >65% predicted with no or 
minimal interstitial lung disease based on reviews 
of imaging studies by [CONTACT_976] [INVESTIGATOR_214058] .   
 
 
Exclusion criteria:  
• Prohibited from normal activity due to wheelchair 
bound status, bed bound status, reliance on a 
cane/walker, activity -limiting angina, activity -
limiting osteoarthritis, or other condition  that limits 
activity . 
• Pregnancy  
• Diagnosis of PAH etiology other than idiopathic, 
heritable, or associated  
• Functional class IV heart failure  
• Requirement of > 1 diure tic adjustment in the 
prior three months  
• Preferred form of activity is not measured by [CONTACT_541341] (swimming, yoga, ice skating, stair 
master, or activities on wheels such as bicycling 
or rollerblading)                                                   
PRIMARY ENDPOINT:   
• Change from baseline mean daily step count at 
week 12.  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  3 
Protocol Date: 08/06/2019  SECONDARY ENDPOINTS:   
• Change from baseline of six minute walk test 
distance (meters) at week 12.  
• Change from baseline of RV free wall longitudinal 
strain at week 12 (RV Strain).  
• Assess the frequency that the daily step target 
was achieved over 12 weeks (Daily goal 
attainment).  
• Change in minutes of activity per day between 
week 12 and baseline (Daily aerobic time).  
• Change in survey score between week 12 and 
baseline (emPH asis-10 Quality of Life survey)  
• Change in survey score between week 12 and 
baseline (SF -36 Quality of Life Mental 
Component Score).  
• Change in Borg Dyspnea Score between week 12 
and Baseline.  
• Change in heart rate between week 12 and 
Baseline (Resting heart rate).  
• Change from baseline insulin resistance at week 
12 (HOMA -IR). 
• Change from baseline B -type natriuretic  peptide 
level at week 12 (BNP).  
• Change in SF -36 score between week 12 and 
Baseline (SF -36 Physical Component Score).  
• Change in minutes between week 12 and 
baseline in minutes of moderate -vigorous activity.  
• Change in fat volume between week 12 and 
baseline (visceral fat volume).  
 
• OBSERVATIONS:    
• Subjects will be evaluated in person at screening, 
baseline, 12 weeks.  
• Subjects will have telephone follow -ups at 2, 4, 6, 
8, and 10 weeks.  
• BNP levels, other biomarkers will be assessed at 
baseline and 12 weeks.  
• Subjects will have six mi nute walk testing at 
baseline and 12 weeks.  
• Subjects will have a transthoracic 
echocardiogram at baseline and 12 weeks.  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  4 
Protocol Date: 08/06/2019  • Subjects will have a Dual -Energy X -ray 
Absorptiometry (DEXA) at baseline and 12 
weeks.  
• Subjects will answer quality of life questionnair es 
at baseline and 12 weeks.  
SAMPLE SIZE AND POWER:   
A total of 50 subjects will be enrolled with 1:[ADDRESS_705807] 85% power to detect a 25% 
difference at week 12 between the mHealth 
intervention and no intervention groups (α = 0.05).  
DATA ANALYSIS:  
The primary study endpoint will be evaluated using a 
general linear model, adjusting for age, sex, and 
baseline 6MWD. Secondary endpoi nts will be 
evaluated in a similar manner. All univariate analyses 
will be evaluated using t -tests or rank -sum tests and 
χ2 and Fisher’s exact tests as appropriate.  
 
 
 
 
 
 
 
 
 
 
 
 
Brief Table of Contents  
Protocol Summary  ................................ ................................ ................................ ..............  [ADDRESS_705808]  ................................ ................................ ................................ .........................  9 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  5 
Protocol Date: 08/06/2019  
 Background & Significance  ................................ ................................ ....................  [ADDRESS_705809] Selection, and Randomization  ................................ ...............  13 
 Study Designs  ................................ ................................ ................................ ........  14 
 Data Collection  ................................ ................................ ................................ ....... 16 
 Assessments of Efficacy and Outcome Measures  ................................ ................  20 
 Statistical Considerations  ................................ ................................ .....................  24 
 Study Risks and Discomforts  ................................ ................................ .................  26 
 Quality Control  ................................ ................................ ................................ ........  27 
 Data and Safety Monitoring and Reporting  ................................ ........................  28 
 Confidentiality of Study Data  ................................ ................................ ..............  35 
REFERENCES  ................................ ................................ ................................ .................  36 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  6 
Protocol Date: 08/06/[ADDRESS_705810]  ................................ ................................ ................................ .........................  9 
 Background & Significance  ................................ ................................ ....................  10 
1.1 Morbidity, mortality, and limitations of medical therapy in pulmonary arterial 
hypertension. ................................ ................................ ................................ .................  10 
1.2 Functional impairment and efficacy of exercise.  ................................ ................  10 
1.3 Mechanisms of the beneficial effects of physical activity in PAH.  ................  11 
1.4 Mobile health tools to promote behavioral change.  ................................ ....... 11 
 Objectives and Specific Aims  ................................ ................................ .................  12 
2.1 Objectives  ................................ ................................ ................................ ............  12 
2.2 Specific Aims  ................................ ................................ ................................ ....... 12 
Primary Aim:  ................................ ................................ ................................ ................................ ........  12 
Secondary Aims:  ................................ ................................ ................................ ................................ .. [ADDRESS_705811] Selection, and Randomization  ................................ ...............  13 
3.1 Recruitment of Study Sample  ................................ ................................ .............  13 
3.2 Inclusion/Exclusion Criteria ................................ ................................ .................  [ADDRESS_705812] Retention  ......................  13 
 Study Designs  ................................ ................................ ................................ ........  14 
4.1 Overvi ew ................................ ................................ ................................ .............  14 
4.2 Monitoring Device  ................................ ................................ ..............................  14 
4.3 Fitbit Application and Data Management  ................................ ...........................  14 
4.4 mHealth Intervention  ................................ ................................ .........................  15 
4.5 Run-in Period and Step Count Targets  ................................ ...........................  15 
4.6 Remuneration  ................................ ................................ ................................ ...... 16 
 Data Collection  ................................ ................................ ................................ ....... 16 
5.1 Consent  ................................ ................................ ................................ ...............  16 
5.2 Study Visits and Contacts  ................................ ................................ ...................  17 
 Screening Visit ................................ ................................ ................................ ......................  17 
 Study Day – Visit 1 (Baseline)  ................................ ................................ ..............................  17 
 Phone Calls ( Week -1, 2, 4, 6, 8, 10)  ................................ ................................ ...................  18 
 Study Day – Visit 2 (Week 12)  ................................ ................................ ..............................  18 
5.3 Study Schedule of Endpoints and Procedures  ................................ ..................  19 
 Assessments of Efficacy and Outcome Measures  ................................ ................  20 
6.1 Assessments of Efficacy  ................................ ................................ .....................  20 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  7 
Protocol Date: 08/06/2019  
 Step Counts and Physical Activity  ................................ ................................ ........................  21 
6.2 Secondary Outcome Measures  ................................ ................................ ..........  21 
 Six Minute Walk Distance  ................................ ................................ ................................ .... 21 
 Transthoracic Echocardiographic Measures ................................ ................................ ........  22 
 Fidelity of Data Collection and Text Transmission  ................................ ..............................  22 
 The Borg Dyspnea Score  ................................ ................................ ................................ ...... 22 
 Resting Heart Rate  ................................ ................................ ................................ ...............  22 
 Quality of Life Questionnaires (SF36 & emPHasis –10)................................ ....................  22 
 Dual Energy X -ray Absorptiometry (DEXA) ................................ ................................ .......  23 
 Blood Biomarkers  ................................ ................................ ................................ ...............  23 
 WHO Functional Class  ................................ ................................ ................................ ........  23 
 Other Feasibility Endpoints  ................................ ................................ ...............................  23 
 Medication Regimen Escalation/Reduction  ................................ ................................ ..... 24 
 Hospi[INVESTIGATOR_371480] -sided heart failure  ................................ ........  24 
 Death ................................ ................................ ................................ ................................ .... 24 
 Statistical Considerations  ................................ ................................ .....................  24 
7.1 Study design  ................................ ................................ ................................ ....... 24 
7.2 Statisti cal Analysis  ................................ ................................ ..............................  25 
7.3 Missing Data and Dropouts  ................................ ................................ ..............  25 
7.4 Statistical Power  ................................ ................................ ................................  25 
7.5 Interim Monitoring Guidelines  ................................ ................................ .............  26 
7.6 Protocol Violations  ................................ ................................ ..............................  26 
 Study Risks and Discomforts  ................................ ................................ .................  26 
8.1 Activity Tracking  ................................ ................................ ................................ .. 26 
8.2 Echocardiography  ................................ ................................ ...............................  26 
8.3 Venipuncture  ................................ ................................ ................................ ....... 26 
8.4 Privacy  ................................ ................................ ................................ .................  26 
8.5 Financial Risk  ................................ ................................ ................................ ...... 27 
 Quality Control  ................................ ................................ ................................ ........  27 
9.1 Personnel Training  ................................ ................................ ..............................  27 
9.2 Data Quality ................................ ................................ ................................ .........  27 
 Data and Safety Monitoring and Reporting  ................................ ........................  28 
10.1  Consent  ................................ ................................ ................................ ............  28 
10.2  Designated Medical Director  ................................ ................................ ...........  28 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  8 
Protocol Date: 08/06/[ADDRESS_705813] (DSMB)  ................................ ................................  [ADDRESS_705814] Withdrawal  ................................ ................................ ................................ .............  34 
 Unblinding of Intervention Assignment  ................................ ................................ ..............  35 
 Confidentiality of Study Data  ................................ ................................ ..............  35 
11.1  Privacy/Confidentiality Issues  ................................ ................................ .........  [ADDRESS_705815] Retention ................................ ................................ ..... 36 
REFERENCES  ................................ ................................ ................................ .................  36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  9 
Protocol Date: 08/06/[ADDRESS_705816]  
 
Patients with pulmonary arterial hypertension (PAH) have impaired exercise 
capacity and reduced quality of life. Current therapi[INVESTIGATOR_541322], highlighting the need for additional, cost -
effective interventions. Multiple studies have demonstrated that increasing physical 
activity is highly efficacious in PAH, resulting in six -minute walk distance (6MWD) 
improvement that exceeds the effect of medications. However, previously tested 
protocols h ave required inpatient rehabilitation, making them impractical and poorly 
scalable to the general PAH population.  Moreover, cardiopulmonary rehabilitation is not 
reimbursed by [CONTACT_541342] a lternatives to promote physical activity.  
We have shown that daily step counts are markedly reduced in PAH and 
associated with increased adverse events. We have also developed a fully -automated 
mobile health (mHealth) intervention that increased step coun ts in an ambulatory 
cardiology population in a randomized trial. The key feature of the intervention was the 
addition of a “smart text” component delivered to the subject’s smartphone, which 
generated personalized, encouraging content based in behavioral c hange theory (e.g. 
feedback loops and habit formation). This aspect of the mHealth intervention alone 
increased step counts over 300% compared with blinded step count tracking. The 
proposed study will be the first to test the feasibility of a mHealth inter vention in the PAH 
population.   
We propose a randomized trial of step tracking with smart texts versus tracking  
without smart texts  for 12 weeks  to increase step counts in 50 men and women with 
PAH.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  10 
Protocol Date: 08/06/2019  
 Background & Significance  
1.[ADDRESS_705817] (6MWT) 
distance has been used as a  surrogate marker of drug efficacy in PAH, with a 
minimally important distance of about 33m3. Most drug therapy for PAH improves 
6MWT distance approximately [ADDRESS_705818] severely reduced exercise capacity when measured by 6MWT 
distance or cardiopulmonary exercise testing9-15. At diagnosis, mos t PAH patients are 
NYHA functional class III with symptoms of fatigue and shortness of breath with less 
than ordinary activity16. Although once thought to be potentially dangerous17, recent 
studies show exercise to be safe and effective at improving functi onal capacity . It is 
important to consider that in the context of PAH, “exercise” is equivalent to a mild or 
moderate increase in physical activity, such as sustained walking. Thus, the two terms 
can be used interchangeably in reference to this population . In a landmark study, 
Mereles et al. tested an intensive physical activity program in patients with severe PAH 
on stable therapy18. The intervention arm underwent three weeks of inpatient 
rehabilitation involving several hours per day of supervised walking , bicycle ergometer 
training, and dumbbell training followed by a 12 week home program. In the control 
group, the three inpatient weeks involved counseling, relaxation therapy, and activities 
of daily living. 6MWT distance in the intervention arm increased  by 96±61 meters versus 
a decrease of -15±54 meters in the control group (p<0.0001). Importantly, the effect of 
exercise on functional capacity and quality of life is additive to standard medical 
therapy. Since this trial, others have validated the efficac y of inpatient exercise 
programs in PAH19-22. All of these studies have been performed in Europe where 
inpatient (and outpatient) rehabilitation is covered by [CONTACT_541343]. In the [LOCATION_002], major insurers and Medicare do not c urrently reimburse 
cardiopulmonary rehabilitation for pulmonary hypertension.  Therefore, an inpatient 
physical activity program is infeasible in the [LOCATION_002]23. Moreover, the intensity of 
these interventions and requirement for travel make them impractical for many patients 
and poorly scalable to the general PAH population. These studies provide important 
evidence for the efficacy of increasing physical activity,  but the methods present 
significant obstacles to widespread adoption, underscoring the need for more pragmatic 
interventions.  
 
 
 
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  11 
Protocol Date: 08/06/[ADDRESS_705819] reduction in estimated 
pulmonary arterial pressure (3 -5mmHg), suggesting that physical activity do es not 
ameliorate pulmonary vascular disease18. Potential alternative mechanisms include 
improvement in RV function, systemic metabolism, and/or skeletal muscle function. 
Although increased pulmonary blood flow has  been observed after training 
programs in PAH patients24, the effects on RV function were not described. Thus, it 
is unknown if improved pulmonary flow is due to enhanced RV function. Insulin 
resistance is common in  PAH (even in lean patients) and linked to pulmonary 
vascular disease and RV dysfun ction1,25-28. Increased  physical activity may improve 
insulin resistance, thereby [CONTACT_541344]/or RV 
function. Finally, skeletal muscle metabolism is abnormal in PAH patients, exhibited 
by [CONTACT_541345]2,29-32. Skeletal muscle 
dysfunction contributes to reduced functional capacity in PAH22,32. Physical activity 
improves skeletal muscle function in PAH22,33,34, but has not been tested in the 
context of an unsupervised, pragmatic randomize d trial. This study will be the first to 
probe several potential mechanisms of improved exercise capacity in the context of 
a randomized physical activity intervention in the PAH population.  
1.4 Mobi le health tools to promote behavioral change.  
Mobile health (mHealth) technology has been used to promote behavioral change in 
a wide range of chronic conditions. Physical inactivity is a known modifiable 
cardiovascular risk factor35, yet less than half of the US adult population meets the 
goal of at least 1 50 minutes per week of moderate activity36. A 2012 Cochrane 
review confirmed the efficacy of telephone and web -based interventions to increase 
physical activity37. Recent  advances in mHealth technology – particularly the 
widespread use of Bluetooth compati ble accelerometers – now allow remote 
monitoring of physical activity and real time data tracking. Wearable accelerometers 
provide accurate measurements of steps and activity in three dimensions. These 
devices are popular with consumers and often recommend ed by [CONTACT_13922], but 
there are very limited data on their effectiveness at increasing  activity38-40. The 
Tobacco, Exercise and Diet Management (TEXT ME) trial demonstrated that a 
personalized,  text-based intervention in subjects with coronary heart diseas e 
resulted significant reductions in LDL, blood pressure, and smoking and an increase 
in physical activity41. Also recently, our Co -investigators demonstrated in the 
mActive trial that combining behavioral change based text messages with activity 
tracking led to a marked increase in step counts and aerobic activity42. A key 
innovation of the mActive trial was the addition of “smart” texting that adapted to 
real time activity data. Behavioral change elements such as coaching texts appear 
to be a necessary ad dition to simple activity tracking40. A mHealth activity 
intervention is an attractive approach in PAH for several reasons: 1) PAH is 
associated with baseline functional impairment and proven efficacy of physical 
activity; 2) no requirement for proximity t o a major hospi[INVESTIGATOR_541323];  
3) cost-effective  intervention  compared  with standard  therapy;  and 4) highly  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  12 
Protocol Date: 08/06/2019  amenable  to a multi -site trial, which is critical for Phase III studies in a rare disease. 
Given the success of similar interventions in other populations, testing of a mHealth 
intervention in PAH seems  warranted.  
 Objectives and Specific Aims  
2.1 Objectives  
This is a Phase II, single center, randomized, parallel group trial to demonstrate the 
efficacy of a mHealth intervention in PAH  
2.2 Specific Aims  
Primary Aim:  
1. To determine whether a  mHealth intervention affects  mean  daily step count s at 
week 12  in patients with PAH .  
Secondary Aims:  
• Change from baseline of six minute  walk test 
distance (meters) at week 12.  
• Change from baseline of RV free wall longitudinal 
strain at week 12 (RV Strain).  
• Assess the frequency that the daily step target 
was achieved over 12 weeks (Daily goal 
attainment).  
• Change in minutes of activity per  day between 
week 12 and baseline (Daily aerobic time).  
• Change in survey score between week 12 and 
baseline (emPHasis -10 Quality of Life survey)  
• Change in survey score between week 12 and 
baseline (SF -36 Quality of Life Mental 
Component Score).  
• Change in B org Dyspnea Score between week 12 
and Baseline.  
• Change in heart rate between week 12 and 
Baseline (Resting heart rate).  
• Change from baseline insulin resistance at week 
12 (HOMA -IR). 
• Change from baseline B -type natiurectic peptide 
level at week 12 (BNP).  
• Change in SF -36 score between week 12 and 
Baseline (SF -36 Physical Component Score).  
• Change in minutes between week 12 and 
baseline in minutes of moderate -vigorous activity.  
• Change in fat volume between week 12 and 
baseline (visceral fat volume).  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  13 
Protocol Date: 08/06/[ADDRESS_705820] Selection, and Randomization  
3.1 Recruitment of Study Sample  
Patients will be recruited from the Center for Pulmonary Vascular Disease (CPVD) at 
Vanderbilt University Medical Center. Potentially eligible subjects will be pre -screened 
and informed about that study to determine if they have an interest in enrolling. After the 
initial pre -screening, the subject will provide informed consent before any study 
procedures are performed.  
3.2 Inclu sion/Exclusion Criteria  
Inclusion criteria:  
1) Adults (aged 18 or older)  
2) Diagnosed with idiopathic, heritable, or associated (connective tissue 
disease, drugs, or toxins) pulmonary arterial hypertension (PAH) 
according to World Health Organization consensus recommendations  
3) Stable PAH -specific medication regimen for three month s prior to 
enrollment. Subjects with only a single diuretic adjustment in the prior 
three months will be included  
4) Subjects must have a  Bluetooth capable modern smartphone capable of 
receiving and sending text messages and an active data plan . Study staff 
will provide a temporary smartphone with data plan in the event that a 
participant is otherwise qualified but does not own a smartphone  
5) Forced vital capacity >65% predicted with no or minimal interstitial lung 
disease based on reviews of imaging studies by [CONTACT_976] [INVESTIGATOR_214058] .   
 
 
 
Exclusion criteria:  
1) Prohibited from normal activity due to wheelchair bound status, bed bound 
status, reliance on a cane/walker, activity -limiting angina, activity -limiting 
osteoarthritis, or other condition  
2) Pregnancy  
3) Diagnosis  of PAH etiology other than idiopathic, heritable, or associated  
4) Functional class IV heart failure  
5) Requirement of > 1 diuretic adjustment in the prior three months  
6) Preferred form of activity is not measured by [CONTACT_409987] 
(swimming, yoga, ice skati ng, stair master, or activities on wheels such as 
bicycling or rollerblading)  
3.[ADDRESS_705821] Retention  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  14 
Protocol Date: 08/06/2019  Participants will be assigned to either the intervention or no intervention arms after 
the run -in period in a random manner until 25 participa nts are enrolled into each 
arm. Permuted block randomization stratified by [CONTACT_541346] (I/II vs. III) will be 
used to ensure approximate balance of treatment groups within each stratum over 
time.  Based on our previous studies in PAH subjects in our catchment area, African 
Americans will represent approximately 16% of the study population.  
Randomization will be performed in small blocks, which vary in size. Investigators 
will be unaware of the size or order of the blocks . Projected dropout during the [ADDRESS_705822] is required to 
initiate appropriate therapy of an adverse event (AE) or if the safety of th e subject is at 
serious risk without knowledge of the group assignment. The decision to unmask will be 
made by [CONTACT_978] [INVESTIGATOR_117404]. The Data Safety Monitoring Board will be 
notified as soon as possible . 
 Study Designs  
4.1 Overview  
We propose a randomized trial to examine the feasibility of a  mHealth intervention to 
improve step counts in patients with PAH. Subjects will be randomized to step tracking 
plus smart texts versus tracking with usual activity for 12 weeks.  
4.2 Monitoring Devi ce 
The Fitbit Charge HR tri -axial accelerometer will be used to  continuously gather data on 
physical activity, heart rate, and sleep. This device provides feedback in units of activity 
(steps, stairs climbed, activity time, and exercise time) and heart rat e (per second when 
active, per 5 seconds when inactive). It has been validated against research devices in 
free-living conditions and is relatively inexpensive.  
4.[ADDRESS_705823]'s smartphone, 
paired via Bluetooth 4.0 to the Fitbit Charge HR. The Fitabase subscription service 
(https://www.fitabase.com/) will be used to create a study dashboard, enabling real -time 
monitoring of battery charge, device syncing, and physical activity variables allowing 
real-time monitoring of participant compliance with the study protocol. Fitabase is a 
HIPPA compliant platform th at can link and aggregate the Application Programming 
Interfaces of the Fitbit Charge HR. Real time activity data will be transmitted from the 
subject’s smartphone to our mHealth platform via cellular network. The Charge HR has 
a battery life of [ADDRESS_705824] a data plan, the study may offer to 
purchase a temporary da ta plan for the participant. The study may offer a temporary 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  15 
Protocol Date: 08/06/[ADDRESS_705825]’s smartphone 
to our mHealth platform via cellular network. Subjects  assigned to the texting arm  
will receive 3 texts/day in sync with  their preferred morning, lunch, and evening 
leisure schedule, which is defined at enrollment. These texts will use personal, 
disease -specific, and provider information ( Table 1 ) to deliver [ADDRESS_705826] or memorable cue.
Booster:  
“Megan, you were pretty active 
yesterday! You got 8994 steps, which 
is close to your goal of 10,000. There 
are immediate benefits to exercise: you 
will feel better and  have more  energy!”  Positive reinforcement:  
“Jon, you are on track to have a VERY 
ACTIVE day! Already halfway to your 
target  of 10,000 steps – Outstanding
Subjects in both study arms may receive additional texts during the day for 
reminders about charging, syncing, and the Fitbit Charge HR. Subjects will receive 
weekly email reminders about the importance of wearing their device from a secure 
email address created for this study. Subjects can email this account with study 
questions. If there is loss of data transmission for a full day, subjec ts will be emailed 
with a reminder to wear their device and/or reestablish a connection with their 
phone. After [ADDRESS_705827] 
regularly scheduled clinic visits with their treating physician, they will be counseled 
not to reveal their group assignment.  
4.5 Run-in Period and Step Count Targets  
We will use a two -week run -in 
period, which will improve our ability 
to identify a true b aseline step count 
and reduce dropout after 
randomization. Participants will wear 
the Fitbit Charge  3 HR device 24 
hours a day for seven days a week 
(with the option to remove device 
during showering or bathing ) to 
determine their baseline daily step 
count . We will assume a Hawthorne 
or observer effect during the first 
week of the run -in period and 
discard this data. The baseline daily  
Table 1. Factors in Personalization of Text 
Messages  
Preferred  name  [CONTACT_541361]/partner  
Sex Name [CONTACT_541362]-morbidities  Television  watching  habits  
PAH -specific  medications   
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  16 
Protocol Date: 08/06/2019  step count will be calculated as total steps during run -in Week 2 divided by 7 days. 
Randomization will occur after the run -in phase to account for potential dropout 
during this period.  Participants displaying noncompliance during the run -in period will 
not be randomized. Noncompliance will be defined as having more than one bad data or 
no data day per week. However, depending  on the reason for noncompliance, this 
requirement may be waived at the discretion of the PI [INVESTIGATOR_36749].  
The initial daily step target  Weeks 1 -4 for the intervention group  will be 20% higher 
than the run -in baseline value. For example, if the run -in da ily step count is 2,000 
steps/day, the daily step target for Weeks 1 -4 will be 2,400 steps/day . An increment 
of 20% was selected because it reflects the average increase in treadmill workload 
achieved over 4 weeks in chronic obstructive lung disease patien ts with PH who 
attend pulmonary rehabilitation at our facility.  Average daily step counts during 
Week 4 will be calculated and used to define the target (20% above the Week 4 
average) for Weeks [ADDRESS_705828] an option to receive $200 for completing the study or be paid $[ADDRESS_705829]’s rights and responsibilities if they choose 
to participate in t he trial and their right to refuse to participate.  It will be made clear that 
their clinical care will not be affected by [CONTACT_220862].   
The subject consent process will be conducted either by [CONTACT_648], in person at the 
Vanderbilt Pulmonary Clinic or at t he Vanderbilt Center for Translational and Clinical 
Research, or by [CONTACT_2329] a REDCap -based electronic consent form.  The eConsent form 
has been developed in REDCap, a secure, web -based, HIPAA -compliant, data 
collection platform with a user management system allowing project owners to grant 
and control varying levels of access to data collection instruments and data (e.g. read 
only, de -identified -only data views) for other users. If the subject chooses to complete 
the electronic consent through REDCap, then a link will be emailed to the subject. 
Subject self -initiated accessing of the REDCap consent form may occur via 
smartphone, computer, or other electronic device. If the subject does not have access 
to a computer, then a phone consent will be offered. If the  subject prefers to have a 
hard copy of the consent to review instead of an emailed PDF, it will be mailed to the 
subject.  
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  17 
Protocol Date: 08/06/[ADDRESS_705830] information will be provided (email and phone) for subject to contact a member 
of the key study personnel with questions, pr ior to consent. Subject signatures will be 
obtained using written signature [CONTACT_134650]/cursor. Upon completion of the consent, 
subject will be provided with a copy of their version of the consent document by 
[CONTACT_541347] a hard cop y of the consent. Should the subject 
choose to receive a link to the consent document in lieu of a hard copy (or if they sign 
electronically from a remote location), they will receive a link to a ROCKET site 
containing the consent form appropriate to the v ersion date that they signed.  Signed 
consent documents will NOT be housed electronically on ROCKET.    
5.[ADDRESS_705831]’s medication regimen.  
 Screening  
At time of initial phone or in-person screen ing, all subject questions are adequately 
answered. After consenting, subjects will be mailed or given the Fitbit device and the 
application will be uploaded to their smartphone. The subject will be asked to continue 
wearing the device for [ADDRESS_705832] will be concealed during 
the screening period. The following will be reviewed at time of screening:  
• Informed consent  
• Review inclusion/exclusion criteria  
• Review of medical history  
• Demographic data  
• Review of current med ications  
• WHO functional class  
• Education on FitBit device  
 Study Day – Visit 1 (Baseline)  
Baseline testing will take place over [ADDRESS_705833] approximately 4 hours. Baseline information will be used to characterize the 
participants and to compare the experimental groups with regards to demographics and 
other variables. Eligibility criteria will be confirmed prior to randomization to treatment 
group.  The following procedures will be performed:  
• Transthora cic Echocardiography  
• Six Minute Walk  Test 
• Dual Energy X -ray Absorptiometry (DEXA)  
• Blood collection  
• Quality of Life Questionnaires (SF -36 and emPHasis -10) 
• Vital signs  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  18 
Protocol Date: 08/06/2019  • Physical exam  
• Interim medical history  
• Review current medications  
 
After fasting research labs have been drawn, the subject will have the opportunity to eat 
a snack.  The subject will complete the SF36 and emPHasis -10.  The investigator or 
research nurse will take a history/interim history and perform a physical examination 
including ch ecking vital signs, and review current medications. The subject will perform  
the six minute walk test . Echocardiography and DXA bone density scan will be 
performed.  
All inclusion/exclusion criteria  will be  confirmed by [CONTACT_541348] c an 
be formally randomized. The subject will be randomized to a treatment group using a 
web-based database.  
 Phone Calls ( Week -1, 2, 4, 6, 8, 10)  
The research coordinator will call the subject. Symptoms and potential side effects will 
be assessed and chang es in medications will be reviewed and recorded. Study 
compliance will be assessed and reinforced.  
 Study Day – Visit 2 (Week 12)  
All tests don e at baseline will be repeated at the Week 12 Visit. The following 
procedures will be performed:   
• Transthoracic Echocardiography  
• Six Minute Walk  Test 
• Dual Energy X -ray Absorptiometry (DEXA)  
• Blood collection  
• Quality of Life Questionnaires (SF -36 and emPHasis -10) 
• Vital signs  
• Physical exam  
• Review current medications  
 
After fasting research labs have been drawn, the subje ct will have the opportunity to eat 
a snack. The subject will complete the SF36 and emPHasis -10.  The investigator or 
research nurse will take a history/interim history and perform a physical examination 
including checking vital signs, and review current m edications. The subject will perform  
the six minute walk test . Echocardiography and DXA bone density scan will be 
performed. Subjects will be asked to continue wearing the activity monitor for another 
[ADDRESS_705834] preferred to receive a money  payment as compensation for 
their participation will be  given a prepaid envelope to return the activity monitor 21 days.  
 
 
 
 
 
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  19 
Protocol Date: 08/06/2019   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3 Study Schedule of Endpoints and Procedures  
The table below summarizes the study endpoint assessments and procedures.  
 
Table 2 . Study Procedures  
 Screening  Run-In Treatment Period  Wash 
Out 
Week -2 to -4 Week 
-2 Week 
-1 Week  
1 Week
2 Week
4 Week
6 Week
8 Week
10 Week 
12 Week 
15 Week 
17 
Visit #     1      2   
Telephone Call #    1  2 3 4 5 6  7 8 
Day#  (-14 to -30 
days to Study 
Hour 0)  -14 to  
-30 -7 to   
-23 0 14  3 28  3 42  3 56  3 70   
3 84  3 105  
3 119   
3 
Informed Consent  X            
  Run-In   X X          
  Randomization     X         
  Wash -Out            X  
  Follow -Up            X 
  History And Physical Exam     X      X   
    Medical History  X   X      X   
    Symptom Assessment     X X X X X X X X X 
    Medications  X   X X X X X X X X X 
    Vital Signs     X      X   
    Physical Exam     X      X   
    WHO Functional Class  X   X      X   
Testing              
    Phlebotomy     X      X   
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  20 
Protocol Date: 08/06/2019        Glucose & Insulin     X      X   
      Fatty Acid &  
      Acylcarnitine  Profiles     X      X   
    NT-proBNP     X      X   
    DXA    X      X   
    Six Minute Walk Test     X      X   
    SF-36, emPHasis -[ADDRESS_705835]  
    (women only)  X            
Study Procedures              
    Adverse E vents      X X X X X X  X 
    Compliance   X X  X X X X X X X  
 Assessments of Efficacy and Outcome Measures  
6.1 Assessments of Efficacy  
Primary Outcome Measure(s) : Daily Step Count (Time Frame: 12 weeks)   
 
Secondary Outcome Measure(s) :  
There are several secondary objectives of this study. They include:  
• To assess the effect of a mHealth intervention  on frequency of daily goal 
attainment at week 12 . 
• To assess the effect of a  mHealth intervention vs. no intervention on daily aerobic 
time at week 12.  
• To assess the effect of a  mHealth intervention vs. no intervention on total daily 
activity  at week 12.  
• To assess the effect of a  mHealth intervention vs. no intervention on 6MWD at 
week 12.  
• To assess the effect of a  mHealth intervention vs. no i ntervention on Borg Dyspnea 
Score at week 12.  
• To assess the  effect of a  mHealth intervention vs. no intervention on resting heart 
rate at week 12.  
• To assess the effect of a  mHealth intervention vs. no intervention on the SF36 and 
emPHasis -10 at week 12.  
• To assess the effect of a  mHealth intervention vs. no intervention on RV free wall 
longitudinal strain at week 12.  
• To assess the effect of a  mHealth intervention vs. no intervention on tricuspid 
annular plane systolic excursion (TAPSE) at week 12.  
• To as sess the effect of a  mHealth intervention vs. no intervention on tricuspid 
annular velocity (S’) at week 12.  
• To assess the effect of a  mHealth intervention vs. no intervention on HOMA -IR at 
week 12.  
• To assess the effect of a mHealth intervention vs. no intervention on BNP at week 
12.  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  21 
Protocol Date: 08/06/2019  • To assess the effect of a mHealth intervention vs. no intervention on skeletal 
muscle and fat mass at week 12.  
• To assess the effect of a  mHealth intervention vs. no int ervention on WHO 
functional classification for PAH at week 12.  
• To assess the fidelity of data collection and text transmission  of a mHealth 
intervention  over 12 weeks.  
• To assess the effect of a mHealth intervention vs. no intervention on patient 
satisfac tion at week 12  
• To assess the effect of a mHealth intervention vs. no intervention on dropout rates 
over 12 weeks.  
• To assess the effect of a mHealth intervention vs. no intervention on PAH-related 
hospi[INVESTIGATOR_541324] 12 weeks.  
• To assess the effect of a mHealth intervention vs. no intervention on medication 
regimen escalation/reduction over 12 weeks.  
• To assess the effect of a mHealth intervention vs. no intervention on incidence of 
death over [ADDRESS_705836] measure of physical activity in patients’ day -to-day lives.   
Step counts and p hysical activity will be measured using the Fitbit Charge HR monitor, 
a lightweight device that has a three -axis acceleration sensor, altimeter, vibration motor, 
and optical heart rate monitor. This device provides feedback in units of activity (steps, 
stairs climbed, activity time, and exercise time) and heart rate (per second when active, 
per 5 seconds when inactive ). Initialization and data download will be perform ed using 
the Fitbit Application Program Interface.  Step counts will be (1) tracked by [CONTACT_541349], (2) transmitted to the participant’s smartphone via Bluetooth, and (3) 
finally transmitted from the subject’s smartphone to our mHealth platf orm via cellular 
network.  
Subjects will begin wearing the Fitbit on the day of their screening visit and will wear it 
for the next 17 weeks. Participants will wear the Fitbit Charge HR device 24 hours a day 
for seven days a week (excluding only bathing/ showering  and charging ), starting on the 
day after the screening visit and for the next 17 weeks. In addition to absolute step 
counts, we will assess frequency of goal attainment, d aily aerobic time ( total time spent 
walking continuously for > 10 minutes with out breaking for > 1 minute ), and total daily 
activity (time spent above 3 metabolic equivalents)  
6.[ADDRESS_705837] of unencouraged, self -determined distance 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  22 
Protocol Date: 08/06/[ADDRESS_705838]’s smartphone via Bluetooth, and then sent out to our mHealth 
platform via c ellular network.  
 The Borg Dyspnea Score  
In order to assess exercise capacity, the Borg score for dyspnea and overall fatigue will 
be recorded before and after subjects complete the six -minute walk, performed at 
baseline and week 12. This score is a measure  of the physical activity intensity level 
based on the subject's perceived exertion. Subjects will rate at resting and peak 
exercise.  
  Resting Heart Rate  
Resting heart rate will be monitored regularly using the activity tracking device (per 
second when act ive, per 5 seconds when inactive). In addition, subject's heart rate will 
be measured will be  recorded before and after subjects complete the six -minute walk 
test. This will provide resting and peak exercise heart rate at baseline and week 12.  
  Quality of Life Questionnaires (SF36 & emPHasis –10) 
The SF36 is one of the most widely used generic measures of subjective health 
status. The SF36 includes one multi -item sc ale that assesses eight health concepts: 
1) limitations in physical activities because of health problems; 2) limitations in 
social activities because of physical and emotional problems; 3) limitations in usual 
role activities because of physical health pr oblems; 4) bodily pain; 5) general mental 
health (psychological distress and well -being); 6) limitations in usual role activities 
because of emotional problems; 7) vitality (energy and fatigue); and 8) general 
health perceptions. Subjects will complete the  SF36 at baseline and each 
subsequent clinic visit during the therapy phase of the study.  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  23 
Protocol Date: 08/06/2019  The emPHasis -10 is a pulmonary hypertension -specific questionnaire to assess 
health related quality of life. It covers breathlessness, fatigue and lack of energy, 
social restrictions, and concerns regarding effects on patient’s significant others, 
such as family and friends50. Each item is scored on a semantic differential six -point 
scale (0 -5), with contrasting adjectives at each end. A total emPHasis -10 score is 
derived using simple aggregation of the 10 items. emPHasis -10 scores range from 
0 to 50, higher scores indicate worse quality of life50. 
  Dual Energy X -ray Absorptiometry (D EXA) 
DXA is the technique most commonly used to assess bone density in adults. The 
lumbar spi[INVESTIGATOR_371486]. The technique uses very 
low-dose x -ray exposures (<4µSv per scan) and measurements are rapid.  Body 
composition will be asses sed at baseline and 12 weeks  for changes in relative lean 
muscle and body fat ma ss.   
  Blood Biomarkers  
a. Plasma NT -proBNP  
Plasma NT -proBNP reflects right ventricular function in PAH and is a strong 
predictor of outcome in PAH.  BNP will  be assessed at baseline  and 12 weeks.   
b. HOMA -IR 
Insulin resistan ce will be quantified using the homeostasic model assessment of 
insulin resistance (HOMA -IR), which estimates insulin resistance through fasting 
plasma insulin and glucose ratios, at baseline and [ADDRESS_705839] of this intervention on fatty acid metabolism, we will measure 
fasting long -chain fatty acid and acylcarnitine profiles using mass spectrometry at 
baseline and 12 weeks .  
 WHO Functional Class  
The WHO functional classification for PAH has been modified from th e well -known 
[LOCATION_001] Heart Association functional classification. This functional classification is 
based on symptoms, with Class I being defined by [CONTACT_341886], Class II as having 
mild limitation in physical activity, Class III as having markedly limited  physical 
activity and Class IV as being unable to perform any physical activity. The WHO 
functional class will be assessed at every visit.  
 Other Feasibility Endpoints  
a. Drop Out Rates  
b. Patient Satisfaction: Patient satisfaction will be assessed using a 
customized survey developed for the mActive trial and adapted for the PAH 
population.  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  24 
Protocol Date: 08/06/2019  
 Medication Regimen  Escalation/Reduction  
The addition of new therapy for PAH indicates disease worsening (or subsequent) right 
heart failure. New PAH -specific medications add ed to the subjects’ medical regimen 
and the dates when added will be recorded during the study. Often, specific PAH 
medications which are administered at a stable dose have increased dosing with clinical 
worsening (specifically, prostacyclin analog therapy ). All dose changes will therefore be 
recorded.  
 Hospi[INVESTIGATOR_371480] -sided heart failure  
A hospi[INVESTIGATOR_371481]/or right -sided heart failure will be 
defined as a hospi[INVESTIGATOR_541325]/or PAH 
symptoms (e.g., syncope) refractory to outpatient increases in dose or frequency of 
diuretics or specific PAH medications.  
We will record all hospi[INVESTIGATOR_371483]. Records from each 
hospi[INVESTIGATOR_541326]. These records will be 
reviewed by [CONTACT_371508].  
 
 
 Death  
Cardiovascular Death: We define as cardiovascular death as:  
1) sudden death  
or 
2) death preceded by:  
a) cardiogenic shock (hypotension resulting in a failure to maintain normal 
renal or cerebral function for >15 minutes prior to death)  
     or 
3) heart failure symptoms or signs requiring:  
i) intravenous therapy or oxygen in the hospi[INVESTIGATOR_541327]) confinement to be d 
in the absence of secondary causes (such as systemic infection or dysfunction of 
intravenous or subcutaneous medication delivery devices) or alternative causes 
of death.  
Non-Cardiovascular Death: A death which does not meet the criteria above will 
be co nsidered a non -cardiovascular death.  
 Statistical Considerations  
7.[ADDRESS_705840] a single -blinded, randomized, parallel group trial. 
Step counts, activity, 6MWT, SF -36, emPHasis -10, DXA scanning, and blood sampling 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  25 
Protocol Date: 08/06/[ADDRESS_705841] – the proportional odds ordinal logistic model. The effects of the 
baseline value and age will be assumed to be smooth but not linear by [CONTACT_541350].   
 
7.3 Missing Data and Dropouts  
For all endpoin ts, the primary analysis will be intention -to-treat: all subjects 
randomized with a post -intervention endpoint measurement will be included. For 
endpoints based on measurements collected at the end of the study, individuals 
who do not complete follow -up ca nnot be included in analyses of those endpoints. A 
per-protocol analysis will be conducted as a secondary analysis for the primary 
endpoints. Any subject who is identified as a major protocol violator will not be 
included. Major protocol violators will be defined as subjects randomized but non - 
compliant with wearing the accelerometer (i.e. missing ≥ ½ of total days).  
A multiple imputation procedure implemented in the aregImpute function in the 
Hmisc package in R (R Package; Version 3.0 -10) will be used to  assess the impact 
of missing data. The analysis with imputation will serve primarily as a sensitivity 
analysis. We will conservatively impute missing data to perform analyses with and 
without imputed missing data to corroborate findings. Conservative impu tation 
strategies could include assuming worst case scenario for subjects on the 
intervention, best case for subjects on the control, or assuming the observed mean 
of the control group for the subjects on the intervention. The potential drop -out is 
conside red in the power calculation to minimize its impact.  
7.[ADDRESS_705842] 80% or 90% power, 
respectively, to detect a 25% difference using a t -test with a 0.05 two -sided 
significance level. In this calcu lation, we conservatively assumed no change for the 
control group (conservative because 6MWT distance often declines in placebo 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  26 
Protocol Date: 08/06/2019  groups in PAH trials) and a within subject correlation of 0.7. Assuming a 10% drop 
out rate, we plan to enroll [ADDRESS_705843] 85% power.  
7.[ADDRESS_705844] confidentiality policy and the technology system we use to 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  27 
Protocol Date: 08/06/2019  deliver text me ssages meets or exceed HIPAA standards, there is a possibility for the 
text messaging communications to be intercepted or accessed without the participant’s 
authorization. Once delivered to the participant’s mobile device, text messages are 
under his or he r control and are his or her responsibility. By [CONTACT_541351], participants accept this technology risk and release the research team, 
Vanderbilt, and Johns Hopkins from any liability arising from the use of text message 
communicati ons in this program.  
 
8.[ADDRESS_705845] in the study protocol, each site PI [INVESTIGATOR_541328] (and local IRB approvals, if required) is completed and available. The purpose 
of training is to ensure that study personnel are carrying out the protocol in a consistent 
way and are adherin g to good clinical practice guidelines. Staff will have current Human 
Subjects Training Certification on file. Before enrollment begins, study coordinators and 
research assistants who will perform the outcome assessments will be trained in all 
procedures, including completion of case -report forms (CRFs).  
9.[ADDRESS_705846], having subjects report any adverse event to the 
study team, and having subjects undergo vital sign checks and physical exams during 
each study visit.  The research team will create computer modules to identify 
discrepancies and incomplete data. These reports are tracked until each problem is 
resolved and corrected in the database.  
All study personnel are req uired to read the consent form and protocol.  
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  28 
Protocol Date: 08/06/[ADDRESS_705847]’s r ights and responsibilities if they choose to participate in the trial and their 
right to refuse to participate.  It will be made clear that their clinical care will not be 
affected by [CONTACT_220862].  Subjects will be permitted to provide verbal consent ov er the 
phone prior to being scheduled for a screening visit. Documentation of verbal consent 
will be noted.  Written consent will be obtained at t he screening visit or before.   
10.[ADDRESS_705848] 
will include questions about excessive breathlessness with exertion, dizziness, 
presyncope/syncope, excessive fatigue , muscle soreness, increased use of as needed 
diuretics, orthopnea, and paroxysmal nocturnal dyspnea. Any positive responses will be 
reviewed with the medical director who will discuss these concerns with the subject to 
determine whether the symptoms are r elated to the intervention. If symptoms are likely 
attributable to the intervention, we will record it as an adverse event and decrease the 
step count goal to a tolerable level , depending  on the severity of the symptoms and the 
judgement of the medical director. All serious adverse events will be reported to the 
DSMB, Vanderbilt Institutional Review Board, and NIH as described in Section 10.5.4.  
10.[ADDRESS_705849] (DSMB)  
An independ ent Data Safety Monitor Board (DSMB) will monitor the trial. The aims of 
the DSMB are to safeguard the interests of the trial's participants, potential participants, 
and investigators, to ensure the safety of the trial's interventions, to monitor the trial 's 
overall conduct, and protect the trial's validity and credibility. The DSMB membership 
consists of [ADDRESS_705850] been chosen because of their experience in 
clinical trials and/or clinical expertise, and have been approved by [CONTACT_978] [INVESTIGATOR_55532] e team 
of Co -Investigators. The members are independent of the trial (e.g., not be involved with 
the trial in any other way or have any involvement that could impact the trial).The 
members of the DSMB are : Roham Zamanian, MD, FCCP  (Chair), Steven Kawut, MD , 
MS, Paul Nietart, PhD, Joseph Fanning, PhD, and Mary Beth Brown, PT, PhD.  The first 
meeting will be an organizational meeting via teleconference.  It will be left to the 
discretion of the DSMB whether to subsequently meet face -to-face or by 
[CONTACT_541352] #: 4.3  29 
Protocol Date: 08/06/[ADDRESS_705851], t he letter to the PI [INVESTIGATOR_541329].    
 
 
 
 
10.5 Safety and Adverse Events  
 Definitions  
• Unanticipated Problem (UP ): Any incident, experience, or outcome that meets 
all of the following criteria:  
1. unexpected (in terms of nature, severity, or frequency) given a) the 
research procedures that are described in the protocol -related documents, 
such as the IRB -approved research protocol and informed consent 
document; and b) the characteristics of the subje ct population being 
studied;  
2. related or possibly related to participation in the research (Possibly related 
to participation in the research means there is a reasonable possibility that 
the AE, experience, or outcome may have been caused by [CONTACT_541353] ); and  
3. suggests that the research places subjects or others at a greater risk of 
harm (including physical, psychological, economic, or social harm) than 
was previously known or recognized.    
 
• Adverse Event (AE) :  Any symptom, sig n, illness or experience that develops or 
worsens in severity during the course of the study.  Intercurrent illnesses or 
injuries should be regarded as AEs.  Abnormal results of diagnostic procedures 
are considered to be AEs if the abnormality:  
 results in study withdrawal  
 is associated with a serious AE  
 is associated with clinical signs or symptoms  
 leads to additional treatment or to further diagnostic tests  
 is considered by [CONTACT_541354] #: 4.3  30 
Protocol Date: 08/06/2019  • Serious Adverse Event (SAE):  Advers e reactions are classified as serious or 
non-serious.  A serious adverse event  is any AE that is:  
 fatal 
 life-threatening  
 requires or prolongs hospi[INVESTIGATOR_541330]  
 a congenital anomaly or birth defect  
 an important medical event  
Important medical events are those that may not be immediately life threatening, but 
are clearly of major clinical significance. They may jeopardize the subject, and may 
require intervention to prevent one of the other ser ious outcomes noted above.  For 
example, drug overdose or abuse, a seizure that did not result in in -subject 
hospi[INVESTIGATOR_5108].  
All AEs that do not meet any of the criteria for serious should be regarded as non-
serious AEs .  
• Suspected Adverse Reaction:  Any adverse event for which there is a 
reasonable possibility that the drug caused the adverse event.  For reporting 
purposes, "reasonable possibility" mean s there is evidence to suggest a causal 
relationship between the drug/investigational product and the adverse event.  
 Classifying AEs  
Severity  
The intensity of the AE is classified according to the Common Terminology Criteria for 
Adverse Events v4.0 ( CTCAE v4.0).  Grade refers to the s everity (intensity) of the AE:  
If the intensity of an AE worsens during study drug administration, only the worst 
intensity should be reported on the AE page. If the AE lessens in intensity, no chan ge in 
the severity is require d. 
CTCAEv4 Grade 1 : mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention is not indicated.  
CTCAEv4 Grade 2 : moderate ; minimal, local, or noninvasive intervention is 
indicated; limiting to age -appropriate instrumental activities of daily living (ADL; 
instrumental ADL refers to preparing meals, shoppi[INVESTIGATOR_3112], 
using the telephone, managing money, etc).  
CTCAEv4 Grade 3 : severe or medically significant but not immediately life 
threatening; hospi[INVESTIGATOR_39676]; 
disabling; limiting to self -care ADL (self -care ADL refers to bathing, dressing and 
undressing, feeding self, using the toilet, taking medications, and not bedridden).  
CTCAEv4 Grade 4 : life-threatening  consequences; urgent intervention is 
indicated.  
CTCAEv4 Grade 5 : death  due to an AE.  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  31 
Protocol Date: 08/06/2019  In this grading system, severity is not equivalent to seriousness.  For example, a SAE 
would be any event which was life -threatening or disabling (Grade 4) or f atal (Grade 5) 
or was moderate -severe (Grade 2 -3) and required or prolonged hospi[INVESTIGATOR_059].  
Expectedness  
AEs must be assessed as to whether they were expected to occur or were unexpected, 
meaning not anticipated based on current knowledge found in the pro tocol, investigator 
brochure, product insert, or label.  
Expected:  an AE known to be associated with the interve ntion or condition under study.  
OHRP defines an unexpected AE  as any AE occurring in one or more subjects 
participating in a research protocol, the nature, severity, or frequency of which is not 
consistent with either:  
1) the known or foreseeable risk of AEs associated with the procedures involved in 
the research that are described in a) the protocol -related documents, such as the 
IRB-approved research protocol, any applicable investigator brochure, and the 
current IRB -approved informed consent document, and b) other relevant sources 
of information, such as product labe ling and package inserts; or  
2) the expected natural progression of any underlying disease, disorder, or 
condition   of the subject(s) experiencing the AE and the subject’s predisposing 
risk factor profile for the AE.  
3) Relatedness  
 1) Definite:  the AE is clear ly related to the research procedures  
 2) Probably: the AE is likely related to the research procedures  
 3) Possible: the AE may be related to the research procedures  
 4) Unlikely: the AE is doubtfully related to the research procedures  
 5) Unrelated: the AE is clearly not related to the research procedures  
 
Possibly related to participation in the research: There is a reasonable possibility 
that the adverse event, experience, or outcome may have been caused by [CONTACT_9156].    
For each identified AE, an AE entry on the appropriate form will be completed using the 
above classifications as soon as possible, updating as necessary. Reporting procedures 
should be started immediately (within 24 hours)  upon learning of a SAE or UP.  
 Interpretation of Definitions  
AE and UP Reporting Period  
The study period during which AEs must be reported is normally defined as the period 
from the initiation of any study procedures to the end of the study treatment follow -up.  
For this study, the study treatment follow -up is defined as [ADDRESS_705852] 
administration of study treatment (week 15 phone call).   
Preexisting Condition  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  32 
Protocol Date: 08/06/2019  A preexisting condition is one that is present at the start of the study.  A preexisting 
condition should be recorde d as an AE if the frequency, intensity, or the character of the 
condition worsens during the study period.  
General Physical Examination Findings  
At screening, any clinically significant abnormality should be recorded as a preexisting 
condition.  At the end  of the study, any new clinically significant findings/abnormalities 
that meet the definition of an AE must also be recorded and documented as an AE.   
Post -study AE  
All unresolved SAEs or AEs that are possibly, probably, or definitely related to the study 
or study drug should be followed by [CONTACT_1374], the 
subject is lost to follow -up, or the AE is otherwise explained.  At the last scheduled visit, 
the investigator should instruct each subject to report any subsequent event(s) that the 
subject, or the subject’s personal physician, believes might reasonably be related to 
participation in this study.   
 
Abnormal Laboratory Values  
Labor atories will not be drawn unless clinically indicated.  A clinical laboratory 
abnormality should be documented as an AE if any one of the following  conditions is 
met:  
• The laboratory abnormality is not otherwise refuted by a repeat test to confirm the 
abnormality  
• The abnormality suggests a disease and/or organ toxicity  
• The abnormality is of a degree that requires active management; e.g. change of 
dose, discontinuation of the drug, more frequent follow -up assessments, further 
diagnostic investigation, et c. 
Hospi[INVESTIGATOR_059], Prolonged Hospi[INVESTIGATOR_5109] a serious AE unless specifically instructed otherwise in 
this protocol.  Any condition respons ible for surgery should be documented as an AE if 
the condition meets the criteria for an AE.  Neither the condition, hospi[INVESTIGATOR_059], 
prolonged hospi[INVESTIGATOR_059], nor surgery are reported as an AE in the following 
circumstances:  
• Hospi[INVESTIGATOR_5110] a preexisting condition.  Surgery should not be reported as an 
outcome of an AE if the purpose of the surgery was elective or diagnostic and the 
outcome was uneventful.  
AEs and SAEs which d o not fall under the expedited reporting procedure requirements 
will be reported by [CONTACT_541355]. The I nvestigator/designee 
should keep originals o r photocopi[INVESTIGATOR_267855], including facsimile 
confirmations, and file t hem in the participant's file. The Investigator should ensure that  
all routine AE(s) are reported to ensure the IRB has accurate data for periodic or annual 
reporting requirements.  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  33 
Protocol Date: 08/06/2019  
 Expedited Reporting P rocedures  
The Investigator should notify the IRB, DSMB and NHLBI, in an expedited manner, of 
those events listed in the table below related to study participation.  
Expedited Reporting P rocess  
The PI [INVESTIGATOR_541331] e following  information to the IRB for initial assessment and 
subsequent reporting will occur as outlined on the table.  
• Protocol name [CONTACT_114040]  
• Subject identifiers  
• Demographic data  
• Nature of the event  
• Severity of the event  
• Probable relationship (causality) of AE to study procedure  
• Date and time of AE onset  
• Date and time of AE resolution, if available  
• Concomitant medications that the participant was taking for an 
underlying medical condition or disease and the therapeutic agents 
used for the treat ment of the adverse event  
• Clinical assessment of participant conducted at time of SAE/AE  
• Results of any laboratory and/or diagnostic procedures, and 
treatment  
• Follow -up plan  
• Outcome  
• Autopsy findings (if appropriate)  
 
The IRB will communicate to the PI [INVESTIGATOR_541332]. The PI [INVESTIGATOR_541333]. The PI [INVESTIGATOR_541334].  
 
What Event is 
Reported  Event  By [CONTACT_371515], 
suspected serious 
adverse reactions  
 
 Event   Investigator  • IRB Within 24 hours  of initial receipt of 
information  
IRB 
determination  IRB • Investigator  Within 3 business days  of IRB 
determination  
All events  Investigator  
IRB • NHLBI, DSMB  Within 7 calendar days  of investigator ’s 
initial receipt of information  
Non-fatal, non -life-
threatening 
unexpected, 
suspected serious 
adverse reactions  
  Event  Investigator  • IRB Within 24 hours of initial receipt of 
information  
IRB 
determination  IRB • Investigator  Within 3 business days  of IRB 
determination  
All events  Investigator  
IRB • NHLBI, DSMB  Within 15 calendar days  of investigator’s  
initial receipt of information  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  34 
Protocol Date: 08/06/2019  Unanticipated 
Problem that is not 
an SAE  
  Event  Investigator  • IRB Within 2 business days  of initial receipt of 
information  
IRB 
determination  IRB • Investigator  Within 3 business days  of IRB 
determination  
All events  Investigator  
IRB • NHLBI, DSMB  Within 14 calendar days  of investigator’s 
initial receipt of information  
All Unanticipated 
Problems  All Events  IRB • OHRP  Within 30 days  of the IRB’s receipt of the 
report  
Other Reportable Events:  
The following eve nts are also reportable to the IRB: 
• Any AE that would cause the sponsor to modify the investigators brochure, 
protocol or informed consent form, or wo uld prompt other action by [CONTACT_498687].  
• Information that indicates a change to the risks or potential benefits of the 
research, in terms of severity or frequency. For example:  
– Safety monitoring indicates that a particular side effect is more severe, or 
more frequent than initially expected.  
– A paper is published from another study that shows that an arm of the 
research study is of no therapeutic value.  
• Change in FDA safety labeling or withdrawal from marketing of a drug, device, or 
biologic used in a research protocol.  
• Breach of confidentiality  
• Change to th e protocol taken without prior IRB review to eliminate apparent 
immediate hazard to a research participant.  
• Incarceratio n of a participant when the research was not previously approved 
under Subpart C and the investigator believes it is in the best interest of the 
subject to remain on the study.  
• Complaint of a participant when the complaint indicates unexpected risks or the  
complaint cannot be resolved by [CONTACT_5051].  
• Protocol violation (meaning an accidental or unintentional deviation from the IRB 
approved protocol) that in the opi[INVESTIGATOR_341871], or affects t he rights or welfare of subjects.  
 Subject Withdrawal  
A subject has the right to withdraw from the study entirely at any time for any reason 
without prejudice to future medical care by [CONTACT_267894]. The 
investigator also has the righ t to withdraw subjects from the study in the event of 
concurrent illness, AEs, or other reasons deemed to be in the subject’s best interest.  
A subject should be withdr awn from the study if there is:  
• Withdrawal of consent  
• PI [INVESTIGATOR_541335] s hould be withdrawn for safety  
In order to preserve the integrity of the intention -to-treat analysis, even if the subject is 
withdrawn from the treatment portion of the protocol (either due to subject, physician, or 
investigator decision), it is imperative to continue with the scheduled follow -up 
assessments both for the safety of the subject and for completeness of data collection. 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  35 
Protocol Date: 08/06/[ADDRESS_705853] will be considered, prior to the formal study 
unblinding, only if the following circumstances are met: 1) knowledge of the treatment 
assignment is required to initiate appropriate therapy for an AE or 2) if the safety of the 
subject is at serious risk if the treatment is continued without the knowledge of treatment 
assignment. The decision to unmask will be made by [CONTACT_541356] . The DSMB must be notified of the  decision as soon as possible.  
 Confide ntiality of Study D ata   
In this study, each patient will be assigned a unique Participant ID number (PID)  when 
his/her demographic and race/ethnicity information is ent ered for the first time. Follow -
up data are subsequently entered as needed when a patient has a clinic visit. The 
unique PID number remains with each patient permanently and is matched with all new 
data entered. The PID number and patient identifiers are d irectly linked in the study 
database.  
The study coordinator will also generate a Global Unique Identifier (GUID)  for each  
subject using a NIH tool client. This is an identifying code assigned to a single research 
participant so that data can be compi[INVESTIGATOR_541336] (PII), even if the data are collected at differe nt 
locations or by [CONTACT_371517]. The GUID is created using PII (including, current name, 
legal given name [CONTACT_371521] (first, middle, and last), date of birth, city of birth, state of 
birth, country of birth, and physical sex at birth). Data includ ing the GUID (without other 
identifiers) is considered de -identified by [CONTACT_371518]. Personal identifying 
information used to generate the GUID will be erased by [CONTACT_541357].  
The potential for data  sharing has been included in the informed consent. Data releases 
to investigators for approved research purposes and analyses (after review and 
approval by [CONTACT_541358] a Data Use Agreem ent) will be stripped of identifiers using a “Safe Harbor” 
approach. If an approved investigator has conducted a separate study in which a 
shared participant has also consented to the use of a GUID then this will be retained in 
the data release; however, f or all other data rele ases the GUID will be removed.  
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 
(HIPAA).  Those regulations requir e a signed subject authorization informing the subject 
of the following:  
• What protected health information (PHI) will be collected from subjects in this 
study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  36 
Protocol Date: 08/06/[ADDRESS_705854] vital status (i.e. that the 
subject is ali ve) at the end of their scheduled study period.  
Several mechanisms will be in place to maintain confidentiality. All of the data will be 
reported in aggregate. Each subject in all phases of the study will be assigned a unique 
study Participant Identificati on (PID)  number to be used on all data forms, study 
records, and blood samples. A list of patient names and code numbers will be 
maintained separately in locked file cabinets or on password protected computers. Only 
the investigators and project staff will  have access to this information. No other 
personally identifiable information will be available. We will also obtain a Certificate of 
Confidentiality from the NIH for this study befor e consent of the first patient.  
 
 
11.1 Privacy/Confidentiality Issues  
Consent  forms, medical history data, and study data are stored in secured files, either in 
locked file cabinets or in a locked room separate from medical records and coded such 
that all subject identifiers have been removed. As an additional precaution all HIPAA 
regulated information is stored in an electronic file separate from other study data. Only 
approved study staff (determined by [CONTACT_978] ) will be given authorization to access the 
database. Bio -specimens are processed and labeled with barcode labels that incl ude 
the subjects electronically generated study code and date of sample collection. The bio -
specimens are stored in locked freezers in the study Laboratory; only approved study 
staff has access to the keys for each freezer. Access to the electronic freezer  inventory 
of the specimens is kept on a secure password protected computer.  
11.[ADDRESS_705855] 6 years after study completion, but the pos sibility exists for indefinite 
archival of study information via the REDCap database.  Should the outcome of this 
study prompt future investigations, the participants may be contact[CONTACT_55883] -up 
information and invited to participate in additional  studies.  
REFERENCES  
1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary  
hypertension. Results from a national prospective registry. Ann Intern Med  
1991;115(5):343 –9. 
 
2. Benza RL, Miller DP, Barst RJ, Badesch  DB, Frost AE, McGoon MD. An Evaluation of 
Long -Term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From 
REVEAL. CHEST  2012;  
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  37 
Protocol Date: 08/06/[ADDRESS_705856] for patients w ith pulmonary arterial hypertension. American Journal of 
Respi[INVESTIGATOR_50165]  2012;186(5):428 –33. 
 
4. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol  
(prostacyclin) with conventional therapy for primar y pulmonary hypertension. The Primary 
Pulmonary Hypertension Study Group. N Engl J Med  1996;334(5):296 –302. 
 
5. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial 
hypertension. N Engl J Med  2005;353(20):2148 –57. 
 
6. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial  
hypertension. Circulation  2009;119(22):2894 –903. 
 
7. Ghofrani H -A, Galiè N, Grimminger F, et al. Riociguat  for the treatment of pulmonary 
arterial hypertension. N Engl J Med  2013;369(4):330 –40. 
 
8. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in 
pulmonary  arterial hypertension. N Engl J Med  2013;369(9):809 –18. 
 
9. Taichman DB, Shin J, Hud L, et al. Health -related quality of life in patients with pulmonary 
arterial hypertension. Respir Res  2005;6:92.  
 
10. Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of pulmonary arterial 
hypertension - specific therapi[INVESTIGATOR_014] o n health -related quality of life: a systematic review. 
CHEST  2014;146(3):686 –708. 
 
11. Fernandes CJCS, Martins BCS, Jardim CVP, et al. Quality of life as a prognostic marker in  
pulmonary arterial hypertension. Health Qual Life Outcomes  2014;12:130.  
 
12. Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK. Health -related quality of life 
in patients with pulmonary arterial hypertension. CHEST  2004;126(5):1452 –9. 
 
13. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke -Zaba J. The Cambridge 
Pulmonary Hypertension Outco me Review (CAMPHOR): a measure of health -related 
quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res  
2006;15(1):103 –15. 
 
14. Oudiz RJ, Barst RJ, Hansen JE, et al. Cardiopulmonary exercise testing and six -minute 
walk corr elations in pulmonary arterial hypertension. AJC  2006;97(1):123 –6. 
 
15. Yasunobu Y, Oudiz  RJ, Sun X -G, Hansen JE, Wasserman K. End -tidal PCO2 abnormality 
and exercise limitation in patients with primary pulmonary hypertension. CHEST  
2005;127(5):1637 –46. 
 
16. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline  
charac teristics from the REVEAL Registry. CHEST  2010;137(2):376 –87. 
 
17. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  38 
Protocol Date: 08/06/2019  Respi[INVESTIGATOR_65201]: key concepts and advances in pulmonary rehabilitation. 
American Journal of Re spi[INVESTIGATOR_50165].  2013;188(8):e13 –64. 
 
18. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respi[INVESTIGATOR_541337]. Circulation 2006;114 (14):1482 –9. 
 
19. Ehlken N, Lichtblau M, Klose H, et al. Exercise training improves peak oxygen 
consumption and haemodynamics  in patients with severe pulmonary arterial hypertension 
and inoperable chronic thrombo -embolic pulmonary hypertension: a prospective, 
randomized, controlled trial. European  Heart Journal  2016;37(1):[ADDRESS_705857] of exercise and respi[INVESTIGATOR_541338]. 
Respi[INVESTIGATOR_1516]  2011;81(5):394 –401. 
 
21. Grünig E, Maier F, Ehlken N, et al. Exercise training in pulmonary arterial hypertension 
associa ted with connective tissue diseases. Arthritis Res Ther  2012;14(3):R148.  
 
22. de Man FS, Handoko ML, Groepenhoff H, et al. Effects of exercise training in patients with  
idiopathic pulmonary arterial hypertension. European Respi[INVESTIGATOR_21107]  2009;34(3):669 –
75. 
 
23. Newman JH, Robbins IM. Exercise training in pulmonary hypertension: implications for the 
evaluation  of drug trials. Circulation  2006;114(14):1448 –9. 
 
24. Ley S, Fink C, Risse F, et al. Magnetic resonance imaging to assess the effect of exer cise 
training  on pulmonary perfusion and blood flow in patients with pulmonary hypertension. 
Eur Radiol 2013;23(2):324 –31. 
 
25. Zamanian RT, Hansmann G, Snook S, et al. Insulin resistance in pulmonary arterial  
hypertension. European Respi[INVESTIGATOR_21107]  2009;33 (2):318 –24. 
 
26. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR. Unrecognized 
glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung 
Transplant  2011;30(8):904 –11. 
 
27. West J, Niswender KD, Johnson JA, et al. A potential role fo r Insulin resistance in 
experimental pulmonary hypertension. European Respi[INVESTIGATOR_21107]  2013;41(4):861 –71. 
 
28. Benson L, Brittain EL, Pugh ME, et al. Impact of diabetes on survival and right ventricular  
compensation in pulmonary arterial hypertension. Pulm Circ 2014;4(2):311 –8. 
 
29. Malenfant S, Potus F, Fournier F, et al. Skeletal muscle proteomic signature [CONTACT_541363]. J Mol Med (Berl)  2015;93(5):573 -84. 
 
30. Potus F, Malenfant  S, Graydon C, et al. Impaired angiogenesis and peripheral muscle 
microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. 
American Journal of Respi[INVESTIGATOR_50165]  2014;190(3):318 –28. 
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  39 
Protocol Date: 08/06/2019  31. Malenfant S, Potu s F, Mainguy V, et al. Impaired Skeletal Muscle Oxygenation and 
Exercise Tolerance in Pulmonary Hypertension. Med Sci Sports Exerc  2015;47(11):2273 -
82. 
 
32. Panagiotou M, Peacock AJ, Johnson MK. Respi[INVESTIGATOR_541339]: a role for exercise training? Pulm Circ  2015;5(3):424 –34. 
 
33. Kabitz H -J, Bremer H -C, Schwoerer A, et al. The combination of exercise and respi[INVESTIGATOR_541340]. Lung  
2014;192(2):321 –8. 
 
34. Grünig E, Lichtblau M, Ehlken N, et al. Safety and efficacy of exercise training in various 
forms  of pulmonary hypertension. European Respi[INVESTIGATOR_21107]  2012;40(1):84 –92. 
 
35. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics --2013 up date: a 
report from the American Heart Association. Circulation  2013;127(1):e6 –e245.  
 
36. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to 
reduce cardiovascular risk: a report of the American College of Cardiology/American  Heart 
Association  Task Force on Practice Guidelines. Circulation. 2014;129([ADDRESS_705858]  2):S76 –99. 
 
37. Richards J, Thorogood M, Hillsdon M, Foster C. Face -to-face versus remote and web 2.[ADDRESS_705859] Rev  
2013;9:CD010393.  
 
38. Burke LE, Ma J, Azar KMJ, et al. Current Science on Consumer Use of Mobile Health for 
Cardiovascular Disease Prevention: A Scientific Statement From the American Heart 
Association. Circulation 2015;132(12):1157 –213. 
 
39. Eapen  ZJ, Peterson ED. Can Mobile Health Applications Facilitate Meaningful Behavior 
Change?: Time for Answers. JAMA  2015;314(12):1236 –7. 
 
40. Patel MS, Asch DA, Volpp  KG. Wearable devices as facilitators, not drivers, of health 
behavior  change. JAMA  2015;313(5):459 –60. 
 
41. Chow CK, Redfern J, Hillis GS, et al. Effect of Lifestyle -Focused Text Messaging on Risk 
Factor Modification in Patients With Coronary Heart Disease: A  Randomized Clinical Trial. 
JAMA 2015;314(12):1255 –63. 
 
42. Martin SS, Feldman DI, Blumenthal RS, et al. mActive: A Randomized Clinical Trial of an 
Automated Mobile Health Intervention for Physical Activity Promotion. J Am Heart Assoc 
2015;4(11).  pii:e002239.  
 
43. Pugh ME, Buchowski MS, Robbins IM, Newman JH, Hemnes AR. Physical Activity 
Limitation  as Measured by [CONTACT_541359]. CHEST  
2012;142(6):1391 -8. 
 
44. Bravata DM, Smith -Spangler C, Sundaram V, et al. Using pedometers to increase  physical 
activity and improve health: a systematic review. JAMA  2007;298(19):2296 –304. 
 
mHealth                                                                                                                                Protocol  
Protocol Version #: 4.3  40 
Protocol Date: 08/06/2019  45. ATS statement: guidelines for the six -minute walk test. American Journal of Respi[INVESTIGATOR_112583]  2002;166(1):111 –7. 
 
46. Ware JE, Sherbourne CD. The MOS 36-item short -form health survey (SF -36). I. 
Conceptual framework and item selection. Med Care  1992;30(6):473 –83. 
 
47. Halank M, Einsle  F, Lehman S, et al. Exercise capacity affects quality of life in patients 
with pulmonary hypertension. Lung  2013;191(4):337 –43. 
 
48. Pandey A, Garg S, Khunger  M, et al. Efficacy and Safety of Exercise Training in Chronic 
Pulmonary Hypertension: A Systematic Review and Meta -Analysis. Circulation: Heart 
Failure  2015;8(6):[ADDRESS_705860]  2008;133(1):183 –9. 
 
50. Yorke J, Corris P, Gaine S, Gibbs JSR, Kiely DG, Harries C, Pollock V, Armstrong I. 
emPHasis -10: development of a health -related quality of life measure in pulmonar y 
hypertension. European Respi[INVESTIGATOR_21107] . 2014;43:1106 –1113.  
 
51. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a 
report from the American Society of Echocardiography's Guidelines and Standards 
Committee and the Chamber  Quantification Writing Group, developed in conjunction with 
the European Association of Echocardiography, a branch of the European Society of 
Cardiology. J Am Soc Echocardiogr 2005;18(12):1440 –63. 
 
52. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the e chocardiographic assessment of 
the right  heart in adults: a report from the American Society of Echocardiography endorsed 
by [CONTACT_171476], a registered branch of the European 
Society of Cardiology, and the Canadian Society o f Echocardiography. J Am Soc 
Echocardiogr  2010;23(7):685 –713–quiz786 –8. 
 
53. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left  
ventricular diastolic function by [CONTACT_51541]. J Am Soc Echocardiogr  
2009;22(2):107 –33. 
 
54. Sachdev A, Villarraga HR, Frantz RP, et al. Right ventricular strain for prediction of 
survival in patients with pulmonary arterial hypertension. CHEST  2011;139(6 ):1299 –309. 
 
55. Hardegree EL, Sachdev A, Villarraga  HR, et al. Role of serial quantitative assessment of 
right ventricular function by [CONTACT_541360]. Am J Cardiol  
2013;111(1):143 –8. 
 
 